window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : January 24, 2026

  • News
  • About Us
Contact Us

Clinical Trials

  • Artificial Intelligence,Biotech,Clinical Trials,Diagnostics,Oncology,Precision medicine,Research & Development,Technology and platforms

    SpotitEarly announces strategic partnership with Fox Chase Cancer Center to advance early cancer detection

    SpotitEarly has formed a strategic partnership with Fox Chase Cancer [...]

    January 21, 2026
  • Biotech,Clinical Trials,Funding,Pharmaceuticals and therapeutics

    Infinitopes raises $35 million seed round to advance precision cancer vaccine

    Infinitopes, a clinical-stage biotech developing precision cancer vaccines, has completed [...]

    January 21, 2026
  • Clinical Trials,Infectious Diseases,Research & Development

    Cytespace Africa Labs expands molecular testing capacity to support clinical trials across sub-Saharan Africa

    Cytespace Africa Laboratories has expanded its molecular testing capacity to [...]

    January 21, 2026
  • Clinical Trials,Data Management,Digital Health,Technology and platforms

    Zeroport raises $10 million seed to address remote access security risks in pharma and clinical trials

    Zeroport has raised $10 million in seed funding to expand [...]

    January 20, 2026
  • Artificial Intelligence,Clinical Development,Clinical Trials,Data Management,Digital Health,Research & Development

    Inovalon launches clinical trial eligibility screener to speed up patient recruitment

    Inovalon has launched a new clinical trial eligibility screener aimed [...]

    January 20, 2026
  • Central Nervous System,Clinical Development,Clinical Trials,Oncology,Pharmaceuticals and therapeutics,Regulatory Affairs

    Accord Healthcare disappointed as people with ES-SCLC in Scotland denied access to serplulimab

    Patients in Scotland living with extensive-stage small cell lung cancer [...]

    January 23, 2026
  • Biotech,Central Nervous System,Clinical Development,Clinical Trials,Pharmaceuticals and therapeutics,Rare Diseases

    Exciva raises €51 million Series B to fund phase 2 Alzheimer’s agitation trial

    Exciva GmbH has raised €51 million ($59m) in a Series [...]

    January 20, 2026
  • Artificial Intelligence,Clinical Development,Clinical Trials,Data Management,Digital Health,Pharmaceuticals and therapeutics,Technology and platforms

    From outputs to outcomes: Saama’s Derek Lawrence on why clinical data management must change

    Clinical data management is under pressure to evolve as trials [...]

    January 20, 2026
  • Biotech,Cell & Gene Therapy,Clinical Development,Clinical Trials,Opthalmology,Rare Diseases,Research & Development

    AAVantgarde completes enrollment in LUCE-1 Phase 1 and Phase 2 trial of gene therapy AAVB-081 for Usher syndrome type 1B

    AAVantgarde Bio has completed enrollment in LUCE-1, a first-in-human Phase [...]

    January 16, 2026
  • Clinical Trials,Dermatology,Drug Development,European biotech,Pharmaceuticals and therapeutics

    Almirall to launch phase 3 LumiNE study of lebrikizumab in nummular eczema

    Almirall has announced plans to initiate a phase 3 clinical [...]

    January 15, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • MaaT Pharma randomizes first patient in IMMUNOLIFE Phase 2 NSCLC microbiome study
    Categories: Uncategorised
  • Datwyler, LTS Device Technologies, and Stevanato Group collaborate on large-volume self-administration solutions
    Categories: Biologics & Biosimilars, Drug Delivery & Formulation, Medical devices, Patient Centricity, Pharmaceuticals and therapeutics
  • NeuroVice seizure oral injury device now available through BlinkRx
    Categories: Central Nervous System, Digital Health, Medical devices, Patient Centricity, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top